Topiramate in Migraine Prevention: A 2016 Perspective

Abstract

Topiramate has activity at multiple molecular targets, which may account for why it is effective in migraine and most other, more specific, anticonvulsants are not. Based on randomized controlled trials, topiramate reduces migraine frequency and acute medication use, improves quality of life, and reduces disability in patients with episodic migraine and in those with chronic migraine with or without medication overuse headache. Its efficacy in chronic migraine is not improved by the addition of propranolol. Topiramate's ability to prevent progression from high-frequency episodic migraine to chronic migraine remains unclear. Consistent with clinicians' perceptions, migraineurs are more sensitive to topiramate-associated side effects than patients with epilepsy. Paresthesia is a common occurrence early in treatment but is rarely cause for terminating topiramate treatment. Cognitive problems occur much less frequently than paresthesia but are more troublesome in terms of treatment discontinuation. Cognitive complaints can often be managed by slowly increasing the topiramate dose in small increments to allow habituation. As with other carbonic anhydrase inhibitors, topiramate has metabolic effects that favor the development of metabolic acidosis and possibly renal stones. Because migraineurs have an increased risk of renal stones independent of topiramate exposure, clinicians should counsel all migraine patients to maintain hydration. Abrupt onset of blurring, other visual disturbances, and/or ocular pain following topiramate's initiation should be evaluated promptly since this may indicate rare but potentially sight-threatening idiosyncratic events. Postmarketing evidence has shown that first-trimester exposure to topiramate monotherapy is associated with increased occurrence of cleft lip with or without cleft palate (Pregnancy Category D). Even though topiramate's long half-life would seemingly support q.d. dosing, randomized controlled migraine trials used b.i.d. administration of immediate-release (IR) topiramate, which has more favorable plasma concentration-time profile (ie, lower peak concentrations and higher trough concentrations) than q.d. IR dosing. Given the sensitivity of migraineurs to topiramate-related adverse events, particularly cognitive effects, pharmacokinetic profiles should be considered when optimizing migraine outcomes. The extended-release (XR) formulations Qudexy XR (Upsher-Smith Laboratories) and Trokendi XR (Supernus Pharmaceuticals) were specifically designed to achieve the adherence benefits of q.d. dosing but with more favorable (ie, more constant) steady-state plasma concentrations over the 24-hour dosing interval vs IR topiramate b.i.d. Intriguing results from a study in healthy volunteers showed consistently less impairment in neuropsychometric tests of verbal fluency and mental processing speed with an XR topiramate formulation (Trokendi XR) vs IR topiramate b.i.d. These findings suggest a pharmacodynamic effect associated with significantly reducing plasma concentration fluctuatio...

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials

“…Galcanezumab is well tolerated as over 80% of patients in EVOLVE‐1 and EVOLVE‐2 completed the treatment period and less than 5% of patients discontinued the treatment period due to AEs . This is considerably less than the withdrawal rate due to AEs in registration trials for topiramate (50 mg/day: 17%–18%; 100 mg/day: 19%–27%; 200 mg/day: 21%–34%; and mean dose of 86.0 mg/day: 10.9%), which is a commonly prescribed migraine prevention treatment but similar to other available CGRP monoclonal antibodies …”

Onabotulinumtoxin‐A in Chronic Migraine: Should Timing and Definition of Non‐Responder Status Be Revised? Suggestions From a Real‐Life Italian Multicenter Experience

“…Several classes of medication are used as preventative treatments for migraine (ie, beta blockers, antidepressants, and anticonvulsants) but most of them have no evidence of adequate efficacy in CM. Among oral prophylaxis, only topiramate has been suggested by international guidelines for CM prevention.…”

Intranasally administered IGF-1 inhibits spreading depression in vivo

“…Other means of administration (e.g., intraperitoneal injections and oral gavage) required weeks to affect SD elicited by non-injurious methods (Ayata et al, 2006; Unekawa et al, 2012). A similar time frame for the efficacy of topiramate is observed in patients with episodic migraine (Silberstein et al, 2007; Silberstein, 2017). …”